Abstract: Disclosed is a cap for a container and a container comprising such cap. This container typically accommodates loosely stored, solid products, such as strips, pills, tablets or the like. The cap includes a lid body with a top part and a peripheral wall, wherein the lid body includes a sealing skirt and an inner peripheral wall, which extend from the top part, and form a peripheral groove in between. At least one projection portion for partially covering the peripheral groove is integrally formed with the sealing skirt and the inner peripheral wall.

Abstract: Described herein are novel compositions comprising MT1 and/or MT2 modulators (i.e., inhibitors or activators), and methods using these agents for targeting different T-cell populations, for example, type 1 regulatory (Tr1) CD4+ cells and exhausted CD8+ T-cells cells. Aspects of the invention relate to inhibitors of MT1 and/or MT2 to increase the differentiation of CD4+ cell Trl1 CD4+ cells and increase in the activity of Tr1 cells, e.g., to increase IL-10 production. In alternative embodiments, MT1 and/MT1 inhibitors can be used to increase proliferation and/or activity of exhausted CD8+ T-cells and to decrease CD8+ T-cell exhaustion (e.g., decrease functionally exhausted or unresponsive CD8+ immune cells). Accordingly, aspects of the present invention relate to compositions and methods comprising inhibitors of MT1 and/or MT2 useful in the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune disease.

Abstract: Disclosed is a cap for a container and a container comprising such cap. This container typically accommodates loosely stored, solid products, such as strips, pills, tablets or the like. The cap includes a lid body with a top part and a peripheral wall, wherein the lid body includes a sealing skirt and an inner peripheral wall, which extend from the top part, and form a peripheral groove in between. At least one projection portion for partially covering the peripheral groove is integrally formed with the sealing skirt and the inner peripheral wall.

Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.

Abstract: The present invention is directed to Nogo-A antagonists useful for the control of blood glucose or blood insulin levels in a subject and related use and formulation thereof. In particular, the invention is directed to Nogo-A antagonists useful for the prevention, repression or treatment insulin secretion deficiency and related methods and pharmaceutical formulations. In particular, the invention relates to Nogo-A antagonists useful in the treatment of diabetes mellitus.